1. Purpose
The purpose of this Standard Operating Procedure (SOP) is to establish a comprehensive and controlled system for the receipt, storage, handling, dispensing, documentation, reconciliation, and disposal of Investigational Products (IPs) used in clinical trials.
This SOP ensures that all investigational products are handled in compliance with Good Clinical Practice (GCP), regulatory requirements, and study protocols to maintain product quality, subject safety, and data integrity.
2. Scope
This SOP applies to all personnel involved in the management of Investigational Products at clinical trial sites including:
- Clinical investigators
- Pharmacists or pharmacy staff
- Clinical research coordinators
- Clinical trial support staff
The procedure covers all activities related to Investigational Products from receipt to final destruction or return to sponsor.
3. Definitions
Investigational Product (IP)
A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial.
Accountability
The process of documenting and tracking the receipt, storage, dispensing, return, and disposal of investigational products.
Blinded Study
A study design where participants and/or investigators are unaware of the treatment allocation to minimize bias.
Unblinding
The procedure used to reveal the treatment identity when medically necessary.
4. Responsibilities
Principal Investigator (PI)
- Ensures investigational products are used according to the approved protocol
- Maintains overall accountability and compliance
- Authorizes trained staff to manage IP handling
Pharmacist / Designated IP Custodian
- Receives and verifies investigational product shipments
- Maintains proper storage conditions
- Ensures accurate documentation and accountability
Clinical Research Coordinator (CRC)
- Assists with dispensing and documentation
- Monitors inventory levels
- Ensures compliance with the protocol and SOP
Sponsor / Monitor
- Verifies IP management during monitoring visits
- Confirms accountability and regulatory compliance
5. Procedure
5.1 Receipt of Investigational Products
Upon receipt of investigational products:
- Verify shipment details against the shipping documents and packing list.
- Inspect packages for damage, tampering, or temperature excursions.
- Confirm the following details:
- Product name and code
- Batch/lot number
- Expiry date
- Quantity received
- Record receipt in the Investigational Product Accountability Log.
- Notify the sponsor or study monitor immediately if discrepancies are identified.
5.2 Storage of Investigational Products
Investigational products must be stored according to protocol and manufacturer specifications.
Storage requirements include:
- Secure restricted-access storage area
- Controlled temperature monitoring
- Protection from light, humidity, and contamination
- Segregation from commercial products
Temperature logs must be maintained daily and reviewed regularly.
Any temperature excursion must be documented and reported to the sponsor immediately.
5.3 Inventory Control and Accountability
Accurate records must be maintained for all investigational products.
Accountability documentation includes:
- Receipt records
- Dispensing logs
- Subject-specific dispensing documentation
- Return records
- Reconciliation records
Inventory must be regularly reviewed and reconciled with physical stock.
5.4 Dispensing of Investigational Products
Investigational products should only be dispensed:
- To eligible trial participants
- According to the approved study protocol
- With proper documentation
Before dispensing:
- Verify subject eligibility.
- Confirm randomization or treatment assignment if applicable.
- Record dispensing details including:
- Subject identification number
- Product batch number
- Quantity dispensed
- Date of dispensing
Participants must receive clear instructions regarding dosage, administration, and storage.
5.5 Handling of Blinded Investigational Products
For blinded clinical trials:
- Investigational products must remain blinded unless medically necessary.
- Access to treatment codes must be restricted.
- Emergency unblinding must follow protocol-specific procedures.
All unblinding events must be fully documented and justified.
5.6 Return of Investigational Products
Participants may return:
- Unused investigational products
- Partially used containers
- Empty packaging
Returned materials must be:
- Documented in the accountability log
- Verified against dispensing records
- Stored separately for reconciliation
5.7 Reconciliation of Investigational Products
At regular intervals and at study close-out:
- Physical inventory must be reconciled with accountability records.
- Any discrepancies must be investigated and documented.
- The sponsor or monitor must review reconciliation records.
5.8 Disposal or Return of Investigational Products
Unused or expired investigational products must be handled according to sponsor instructions.
Options may include:
- Return to the sponsor
- Destruction at the study site
- Destruction by an approved third party
Destruction must be documented with:
- Date of destruction
- Quantity destroyed
- Method of destruction
- Witness signature
6. Documentation
The following documents must be maintained:
- Investigational Product Receipt Log
- Temperature Monitoring Records
- Investigational Product Accountability Log
- Dispensing Records
- Return Records
- Reconciliation Documentation
- Destruction Certificates
All records must be accurate, legible, and retained according to regulatory requirements.
7. Deviations
Any deviations from this SOP or the study protocol must be:
- Documented immediately
- Investigated thoroughly
- Reported to the Principal Investigator and Sponsor
Corrective and Preventive Actions (CAPA) should be implemented where necessary.
8. Training
All personnel involved in investigational product management must receive:
- Training on this SOP
- Protocol-specific training
- GCP training
Training records must be maintained.
9. References
- International Council for Harmonisation – ICH E6 (R2) Good Clinical Practice
- Applicable regulatory authority guidelines
- Study Protocol
- Sponsor requirements
FAQs-Handling of Investigational Products
1. What are Investigational Products in clinical trials?
Investigational Products are drugs, biologics, or placebos being tested in clinical research to evaluate safety and effectiveness.
2. Why is proper handling of Investigational Products important?
Proper handling ensures participant safety, regulatory compliance, and accurate study results.
3. Who is responsible for Investigational Product accountability?
The Principal Investigator holds ultimate responsibility, while pharmacists and clinical staff assist in management.
4. What documents are required for IP accountability?
Logs for receipt, dispensing, returns, reconciliation, and destruction.
5. How should Investigational Products be stored?
They must be stored according to temperature, humidity, and security requirements specified by the sponsor.
6. What is an Investigational Product accountability log?
It is a document used to track all IP movements including receipt, dispensing, and return.
7. What happens if there is a temperature excursion?
It must be documented and immediately reported to the sponsor for evaluation.
8. Can Investigational Products be dispensed without documentation?
No. Proper documentation is mandatory for regulatory compliance.
9. What is IP reconciliation?
A process ensuring dispensed, returned, and remaining IP quantities match the records.
10. What is blinded investigational product handling?
A process where treatment allocation remains unknown to maintain study integrity.
11. When is emergency unblinding allowed?
Only when necessary for subject safety.
12. How should unused investigational products be handled?
They should be returned or destroyed according to sponsor instructions.
13. What is the role of monitors in IP handling?
Monitors verify compliance, accountability, and documentation accuracy.
14. What is investigational product dispensing?
The controlled process of providing the study drug to eligible participants.
15. Why is temperature monitoring important?
Improper temperature can compromise drug stability and trial validity.
16. What happens to expired Investigational Products?
They must be documented and destroyed or returned according to sponsor instructions.
17. Who can access Investigational Product storage areas?
Only authorized and trained personnel.
18. What records must be retained after study completion?
All IP accountability and documentation must be retained per regulatory retention requirements.
19. What is Investigational Product destruction documentation?
Records confirming method, date, and quantity destroyed.
20. How often should Investigational Product inventory be checked?
Regular checks should be conducted during monitoring visits and periodic internal reviews.
For more articles, Kindly Click here
For pharmaceutical jobs, follow us on LinkedIn
For Editable SOPs in Word format contact us on info@pharmaceuticalcarrier.com
For more information kindly follow us on www.pharmaguidelines.co.uk
